• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Feasibility and Safety of Neoadjuvant Alectinib in a Patient With ALK-Positive Locally Advanced NSCLC.

作者信息

Zhang Chao, Yan Li-Xu, Jiang Ben-Yuan, Wu Yi-Long, Zhong Wen-Zhao

机构信息

Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.

Department of Pathology, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.

出版信息

J Thorac Oncol. 2020 Jun;15(6):e95-e99. doi: 10.1016/j.jtho.2019.12.133.

DOI:10.1016/j.jtho.2019.12.133
PMID:32471573
Abstract
摘要

相似文献

1
Feasibility and Safety of Neoadjuvant Alectinib in a Patient With ALK-Positive Locally Advanced NSCLC.新辅助阿来替尼治疗ALK阳性局部晚期非小细胞肺癌患者的可行性和安全性
J Thorac Oncol. 2020 Jun;15(6):e95-e99. doi: 10.1016/j.jtho.2019.12.133.
2
Alectinib for ALK-positive non-small-cell lung cancer.阿来替尼用于治疗ALK阳性非小细胞肺癌。
Expert Rev Clin Pharmacol. 2016 Aug;9(8):1005-13. doi: 10.1080/17512433.2016.1195262. Epub 2016 Jun 21.
3
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.阿来替尼对比克唑替尼用于未经治疗的 ALK 阳性非小细胞肺癌。
N Engl J Med. 2017 Aug 31;377(9):829-838. doi: 10.1056/NEJMoa1704795. Epub 2017 Jun 6.
4
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.克唑替尼耐药的间变性淋巴瘤激酶（ALK）重排非小细胞肺癌（NSCLC）患者中艾乐替尼针对全身疾病和脑转移的安全性和活性：一项 1/2 期研究剂量探索部分的结果。
Lancet Oncol. 2014 Sep;15(10):1119-28. doi: 10.1016/S1470-2045(14)70362-6. Epub 2014 Aug 18.
5
Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill.一名病情危急的间变性淋巴瘤激酶重排非小细胞肺癌患者对阿来替尼迅速产生显著反应。
Anticancer Drugs. 2016 Jul;27(6):573-5. doi: 10.1097/CAD.0000000000000356.
6
Alectinib for treatment of ALK-positive non-small-cell lung cancer.阿来替尼用于治疗ALK阳性非小细胞肺癌。
Future Oncol. 2017 Feb;13(4):321-335. doi: 10.2217/fon-2016-0386. Epub 2016 Oct 26.
7
Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.阿来替尼治疗转移性ALK重排非小细胞肺癌的安全性。
Expert Opin Drug Saf. 2017 Apr;16(4):509-514. doi: 10.1080/14740338.2017.1299706. Epub 2017 Mar 3.
8
Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer.阿来替尼：一种用于治疗ALK重排非小细胞肺癌的选择性新一代ALK抑制剂。
Expert Rev Respir Med. 2015 Jun;9(3):255-68. doi: 10.1586/17476348.2015.1009040. Epub 2015 Feb 5.
9
Alectinib surpasses crizotinib for untreated ALK-positive NSCLC.对于未经治疗的ALK阳性非小细胞肺癌，阿来替尼优于克唑替尼。
Lancet Oncol. 2017 Jul;18(7):e377. doi: 10.1016/S1470-2045(17)30482-5. Epub 2017 Jun 15.
10
Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.阿来替尼可挽救先前接受过克唑替尼和色瑞替尼治疗的ALK阳性肺癌患者的中枢神经系统复发。
J Thorac Oncol. 2015 Feb;10(2):232-6. doi: 10.1097/JTO.0000000000000455.

引用本文的文献

1
[Advances of Neoadjuvant Targeted Therapy in ALK-positive Non-small Cell Lung Cancer].[间变性淋巴瘤激酶阳性非小细胞肺癌新辅助靶向治疗的进展]
Zhongguo Fei Ai Za Zhi. 2024 Nov 20;27(11):849-854. doi: 10.3779/j.issn.1009-3419.2024.106.30.
2
What do we know about the role of neoadjuvant targeted therapy in early-stage -mutant and -fused non-small cell lung cancer?-a narrative review of the current literature.我们对新辅助靶向治疗在早期EGFR突变和ALK融合非小细胞肺癌中的作用了解多少？——当前文献的叙述性综述
Transl Lung Cancer Res. 2024 Oct 31;13(10):2813-2827. doi: 10.21037/tlcr-24-359. Epub 2024 Oct 28.
3
A case report: Pathological complete response to neoadjuvant lorlatinib for Epithelioid inflammatory myofibroblastic sarcoma with EML4-ALK rearrangement.
病例报告：新辅助洛拉替尼治疗伴有EML4-ALK重排的上皮样炎性肌纤维母细胞肉瘤的病理完全缓解。
Front Pharmacol. 2024 Jul 31;15:1401428. doi: 10.3389/fphar.2024.1401428. eCollection 2024.
4
Alectinib in Early-Stage Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Current Evidence and Future Challenges.阿来替尼用于早期间变性淋巴瘤激酶阳性非小细胞肺癌：当前证据与未来挑战
Cancers (Basel). 2024 Jul 22;16(14):2610. doi: 10.3390/cancers16142610.
5
Case report: Pathological complete response to neoadjuvant brigatinib in stage III non-small cell lung cancer with rearrangement.病例报告：III期非小细胞肺癌伴[重排类型未提及]患者对新辅助布加替尼治疗的病理完全缓解
Front Oncol. 2024 Jul 11;14:1343238. doi: 10.3389/fonc.2024.1343238. eCollection 2024.
6
Neoadjuvant Lorlatinib Induces Pathological Complete Response in Advanced ALK-Positive Lung Cancer: A Case Report.新辅助 Lorlatinib 诱导晚期 ALK 阳性肺癌病理完全缓解：一例报告。
Am J Case Rep. 2023 Nov 7;24:e942150. doi: 10.12659/AJCR.942150.
7
Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy.病例报告：间变性淋巴瘤激酶（ALK）重排的局部晚期肺腺癌在新辅助阿来替尼治疗期间表现出不一致的影像学表现和病理反应。
Front Pharmacol. 2023 Aug 17;14:1140894. doi: 10.3389/fphar.2023.1140894. eCollection 2023.
8
Pathological complete response to neoadjuvant alectinib in unresectable anaplastic lymphoma kinase positive non-small cell lung cancer: A case report.不可切除的间变性淋巴瘤激酶阳性非小细胞肺癌对新辅助阿来替尼的病理完全缓解：一例报告
World J Clin Cases. 2023 Aug 6;11(22):5322-5328. doi: 10.12998/wjcc.v11.i22.5322.
9
Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports.EML4-ALK重排的肺腺癌对长疗程新辅助阿来替尼的病理完全缓解：2例报告及病例报告的系统评价
Front Oncol. 2023 Jun 20;13:1120511. doi: 10.3389/fonc.2023.1120511. eCollection 2023.
10
Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung Cancer.ALK 重排非小细胞肺癌新辅助 ALK-TKI 治疗后的病理反应和肿瘤免疫微环境重塑。
Target Oncol. 2023 Jul;18(4):625-636. doi: 10.1007/s11523-023-00981-7. Epub 2023 Jun 23.